BioTech IP Review

A world of possibilities

Navigating life sciences and medtech to the extraordinary—driven by creativity, curiosity, and the courage to build a fulfilling journey.

  • Adenovirus‑Based SARS‑CoV‑2 Vaccine

    WO 2021243219 A1 Published: Dec 2, 2021 (priority filing May 29, 2020)Assignee: Janssen (Johnson & Johnson) via its vaccine unitTitle: Adenovirus‑Based SARS‑CoV‑2 VaccineFocus: Genetic constructs and compositions of viral vectors (e.g., adenovirus serotype 26) encoding SARS‑CoV‑2 antigen(s) for vaccination against COVID‑19.…

  • Betacoronavirus mRNA Vaccine

    US10,702,600 B1 Issued: July 7, 2020Assignee: ModernaTX, Inc.Title: Betacoronavirus mRNA vaccineCore Tech: mRNA vaccine coding for SARS‑CoV‑2 spike protein formulated in lipid nanoparticles (LNPs).This patent is widely recognized as covering Moderna’s core Spikevax® COVID‑19 vaccine technology. What the Patent Covers U.S. 10,702,600 B1 protects key…

  • Coronavirus Vaccine Compositions

    WO 2021213945 A1 What This Patent Is About This international patent application covers: 💡 mRNA vaccine compositions 📈 Intended use Why This Patent Is Important 1. Foundation for Comirnaty® COVID‑19 Vaccine 2. Strategic Intellectual Property in mRNA…